MCC-465

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameMCC-465
Drug Alias NameMCC-465
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTopoisomerase (DNA) II alpha inhibitors
TargetsTopoisomerase (DNA) II alpha
Therapy Area/IndicationsStomach Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMitsubishi Tanabe Pharma Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMitsubishi Tanabe Pharma
Active IndicationsN/A
Inactive IndicationsStomach Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A